Cover Image
市場調查報告書

美國的癌症疫苗市場分析

US Cancer Vaccine Market Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 250707
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
美國的癌症疫苗市場分析 US Cancer Vaccine Market Outlook 2022
出版日期: 2016年07月01日 內容資訊: 英文 135 Pages
簡介

本報告提供美國的癌症疫苗市場現況與未來展望相關分析,美國的目前癌症發病情形,癌症疫苗市場結構、特性,主要的產品的開發、銷售情形,市場規模的預測值,今後的市場機會,目前法規環境,主要企業簡介(營業內容、主要策略分析)等調查評估。

第1章 分析師的見解

第2章 分析方法

第3章 癌症患者人口的統計

  • 發病率、盛行率、死亡率
  • 發病率前幾名的州
  • 主要的癌症的發病率
    • 男性的癌症發病率
    • 女性的癌症發病率
    • 兒童的癌症發病率

第4章 市場動態

  • 成長因素
  • 阻礙成長要素
  • 機會

第5章 癌症疫苗市場預測

  • 主要產品分析
    • Provenge
    • T-Vec/Imlygic
    • 人類乳突病毒 (HPV) 疫苗
    • B型肝炎病毒 (HBV) 疫苗

第6章 癌症的各種類的癌症疫苗市場

第7章 各用途的癌症疫苗市場

第8章 癌症疫苗的未來候補:市場機會的評估

  • 預防疫苗
  • 治療疫苗
    • 前列腺癌
    • 乳癌
    • 肺癌
    • 大腸癌

第9章 美國的專利分析

第10章 法規環境

  • 疫苗的認證過程
  • 美國食品藥物管理局 (FDA)的產業的指南:治療用癌症疫苗臨床實驗時的考慮事項
    • 臨床實驗的初期、後期的兩階段的考慮事項
    • 臨床實驗的初期階段的考慮事項
    • 臨床實驗的後期階段的考慮事項

第11章 競爭環境

第12章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Cancer is one of the major health issues faced by the countries across the globe. The researchers are engaged in developing various drugs for the prevention and treatment of the disease. Cancer vaccine is one such example. Since their inception, cancer vaccines were considered as high potential method for preventing and treating cancer. Till date, the vaccines have not been able to achieve the expected sales due to high cost and negative results in clinical trials. However, with launch of new cancer vaccines, such as Imlygic by Amgen; and increasing awareness of people regarding these vaccines, the market is expected to grow.

The US is largest market for cancer vaccines. The growth of the US cancer vaccine market is driven by increasing cancer incidence in the country, rising awareness, and strong pipeline. The “US Cancer Vaccine Market Outlook 2022” report provides detailed analysis of the market. This report covers the present scenario and the growth prospects of US cancer vaccine market for the period 2015-2022. It also covers the drivers, restraints hampering the growth of the market, and future opportunities. Moreover, the report provides the global sales of various cancer vaccines from 2013-2015.

On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. Currently, HPV related cancer vaccines occupy the largest share in the US market.

On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounts for the largest share in 2016. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline. Amongst the various research studies, a vaccine for lung cancer can be expected to come up soon with promising candidates, such as TV4010 and GV1001, having entered phase 3 trials.

The report also provides market share analysis by key players. Merck and GSK are expected to continue to be undisputed market leaders in the cancer vaccine market. Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.

The last section of the report discusses about the key players in the US cancer vaccine market. A brief business overview and financial information about each of these players has been provided in the report. Moreover, this report will help the reader to gain crucial insight into the key players' performances and strategies for growth. Conclusively, the research will prove to be a useful resource for all debut makers in US cancer vaccine industry and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Cancer Statistics by Demographics

  • 3.1. Prevalence, Incidences and Mortality
  • 3.2. Leading States by Incidences
  • 3.3. Leading Cancers by Incidences
    • 3.3.1. Male Cancer Incidences
    • 3.3.2. Female Cancer Incidences
    • 3.3.3. Children Cancer Incidences

4. Market Dynamics

  • 4.1. Drivers
    • 4.1.1. Rising Cancer Incidences
    • 4.1.2. Ability to Reduce Healthcare Expenditure
    • 4.1.3. Rising Awareness
    • 4.1.4. Patient Assistance Programs
    • 4.1.5. Government Initiatives
    • 4.1.6. Strong Pipeline
    • 4.1.7. Technological Advancements
  • 4.2. Restraints
    • 4.2.1. High Cost of Cancer Vaccines
    • 4.2.2. Side Effects of Cancer Vaccines
    • 4.2.3. Vaccine Supply Shortages
    • 4.2.4. Insurance Issues Related to Cancer Vaccination
  • 4.3. Opportunities
    • 4.3.1. Therapeutic Cancer Vaccines
    • 4.3.2. Adjuvant Cancer Vaccines

5. Cancer Vaccines Market Outlook

  • 5.1. Key Product Analysis
    • 5.1.1. Provenge
      • 5.1.1.1. Market Analysis
    • 5.1.2. T-Vec/Imlygic
      • 5.1.2.1. Market Analysis
    • 5.1.3. HPV Vaccine
      • 5.1.3.1. Gardasil
        • 5.1.3.1.1. Market Analysis
      • 5.1.3.2. Cervarix
        • 5.1.3.2.1. Market Analysis
    • 5.1.4. HBV Vaccines
      • 5.1.4.1. Engerix-B
        • 5.1.4.1.1. Market Analysis
      • 5.1.4.2. Recombivax HB
        • 5.1.4.2.1. Market Analysis
      • 5.1.4.3. Pediarix/ Infanrix
        • 5.1.4.3.1. Market Analysis

6. Cancer Vaccines Market by Cancer Type

7. Cancer Vaccine Market by Application

8. Potential Cancer Vaccine Candidates: An Opportunity Assessment

  • 8.1. Prophylactic Vaccine
  • 8.2. Therapeutic Vaccine
    • 8.2.1. Prostate Cancer
    • 8.2.2. Breast Cancer
    • 8.2.3. Lung Cancer
    • 8.2.4. Colorectal Cancer

9. US Patent Analysis

  • 9.1. Patents by Year
  • 9.2. Patents by Category
    • 9.2.1. Utility Patents
    • 9.2.2. Design Patents
    • 9.2.3. Plant Patents
  • 9.3. Patents by Company
  • 9.4. Patents by Assignee Type
    • 9.4.1. By Assignee Name
    • 9.4.2. By Assignee State

10. Regulatory Environment

  • 10.1. Vaccine Approval Process
  • 10.2. FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
    • 10.2.1. Considerations for both Early and Late Phase Clinical Trials
      • 10.2.1.1. Patient Population
      • 10.2.1.2. Monitoring the Immune Response
      • 10.2.1.3. Biomarkers as Evidence of Efficacy
      • 10.2.1.4. Adjuvants Used to Stimulate Immune Response
      • 10.2.1.5. Multi-antigen Vaccines
      • 10.2.1.6. Disease Progression/Recurrence Immediately or Shortly
        • after the Initial Administration of Cancer Vaccines
      • 10.2.1.7. Concomitant and Subsequent Therapies
    • 10.2.2. Considerations for Early Phase Clinical Trials
      • 10.2.2.1. Starting Dose and Dosing Schedule
      • 10.2.2.2. Booster and Maintenance Therapy
      • 10.2.2.3. Dose Escalation
      • 10.2.2.4. Single-arm versus Randomized Phase-2 Trials in Early
        • Development
    • 10.2.3. Considerations for Late Phase Clinical Trials
      • 10.2.3.1. Safety Profile from Early Phase Clinical Trials
      • 10.2.3.2. Endpoints
      • 10.2.3.3. Statistical Issues
      • 10.2.3.4. Control Issues
      • 10.2.3.5. Delayed Vaccine Effect
      • 10.2.3.6. Autologous Vaccine Trials
      • 10.2.3.7. Accelerated Approval Regulations

11. Competitive Landscape

12. Company Profiles

  • 12.1. Merck & Co.
  • 12.2. GlaxoSmithKline plc
  • 12.3. Dendreon (A Subsidiary of Valeant Pharmaceuticals)
  • 12.4. Amgen Inc.

List of Figures:

  • Figure 3-1: Cancer Incidences (Million), 2015-2022
  • Figure 3-2: Cancer Mortality (Million), 2015-2022
  • Figure 3-3: Incidences by Type of Cancer (%), 2016
  • Figure 3-4: States with Highest Cancer Incidences, 2015
  • Figure 5-1: Share of US in Global Cancer Vaccine Market (%), 2016
  • Figure 5-2: US - Cancer Vaccine Market by Product Type (%), 2016
  • Figure 5-3: Global - Provenge Market (Million US$), 2013-2015
  • Figure 5-4: Share of US in Global Imlygic Sales (%), 2015
  • Figure 5-5: Global - Gardasil Market (Million US$), 2013-2015
  • Figure 5-6: US - Gardasil Market (Million US$), 2013-2015
  • Figure 5-7: Share of US in Global Gardasil Sales (%), 2015
  • Figure 5-8: Global - Cervarix Market (Million US$), 2013-2015
  • Figure 5-9: US - Cervarix Market (Million US$), 2013-2015
  • Figure 5-10: Share of US in Global Cervarix Sales (%), 2015
  • Figure 5-11: Global - Engerix-B Market (Million US$), 2013-2015
  • Figure 5-12: US - Engerix-B Market (Million US$), 2013-2015
  • Figure 5-13: Share of US in Global Engerix-B Sales (%), 2015
  • Figure 5-14: Global - Recombivax HB Market (Million US$), 2013-2015
  • Figure 5-15: US - Recombivax HB Market (Million US$), 2013-2015
  • Figure 5-16: Share of US in Global Recombivax HB Sales (%), 2015
  • Figure 5-17: Global - Pediarix/Infanrix Market (Million US$), 2013-2015
  • Figure 5-18: US - Pediarix/ Infanrix Market (Million US$), 2013-2015
  • Figure 5-19: Share of US in Global Pediarix/Infanrix Sales (%), 2015
  • Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2016
  • Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2015-2022
  • Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2015-2022
  • Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2015-2022
  • Figure 7-1: US - Cancer Vaccine Market by Application (%), 2016
  • Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2015-2022
  • Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2015-2022
  • Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
  • Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2016
  • Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
  • Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2016
  • Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2016
  • Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2015
  • Figure 12-1: Merck & Co. - Breakup of Revenue by Segment (%), 2015
  • Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Segment (%), 2015
  • Figure 12-3: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Segment (%), 2015

List of Tables:

  • Table 3-1: Top 10 Cancer Incidences in Males (2015)
  • Table 3-2: Top 10 Cancer Incidences in Females (2015)
  • Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2015)
  • Table 4-1: US - Cancer Incidences (Million), 2015 & 2020
  • Table 5-1: Global - Cancer Vaccine Market (Million US$), 2015-2022
  • Table 5-2: US - Cancer Vaccine Market (Million US$), 2015-2022
  • Table 8-1: Cancers with High Linkage to Virus and Bacteria
  • Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
  • Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
  • Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
  • Table 12-1: Merck & Co. - Key Financials (Million US$), 2013-2015
  • Table 12-2: Merck - Product Portfolio
  • Table 12-3: Merck - Cancer Vaccines in Pipeline
  • Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2013-2015
  • Table 12-5: GlaxoSmithKline - Product Portfolio
  • Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
  • Table 12-7: Valeant Pharmaceuticals International, Inc. - Key Financials (Million US$), 2013-2015
  • Table 12-8: Dendreon - Product Portfolio
  • Table 12-9: Amgen Inc. - Key Financials (Million US$), 2013-2015
  • Table 12-10: Amgen Inc. - Product Portfolio
Back to Top